Skip to main content
Oishi Roychoudhury on Muck Rack

Oishi Roychoudhury

As seen in: Wiley Online Library
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Oishi

Contact Oishi, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Successful Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis, Myositis, and Myasthenia Overlap Syndrome With Baricitinib and Abatacept

|
By Zeinab Alnahas, Sujata Sarkar, Oishi Roychoudhury
| Wiley Online Library Verified
1 Introduction Immune checkpoint inhibitors (ICIs) have shown to improve the outcomes of a wide range of malignancies. ICIs belong to three main categories based on the T cell pathway they target, including anti-programmed cell death-1 (PD1)/anti-programmed cell death ligand-1 (PD-L1), CTLA-4 fusion protein (CTLA-4), and anti-lymphocyte activation gene-3 (LAG-3). Pembrolizumab and dostarlimab are among the many ICIs approved by the FDA [1-3].
Open in Who Shared Issue with article?
See all 1 articles